Science

In recurrent prostate cancer, PSMA PET/CT changes management in two-thirds of cases

In recurrent prostate cancer, PSMA PET/CT changes management in two-thirds of cases

New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients. In initial results from a multicenter trial assessing the impact of 18F-DCFPyL prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), a PET-directed change in management was observed in two-thirds of patients. The research was presented at the Society of Nuclear Medicine and Molecular Imaging’s 2020 Virtual Annual Meeting.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,